0000310158 false 0000310158 2020-07-31 2020-07-31 0000310158 us-gaap:CommonStockMember 2020-07-31 2020-07-31 0000310158 mrk:Sec1.125NotesDue2021Member 2020-07-31 2020-07-31 0000310158 mrk:Sec0.500NotesDue2024Member 2020-07-31 2020-07-31 0000310158 mrk:Sec1.875NotesDue2026Member 2020-07-31 2020-07-31 0000310158 mrk:Sec2.500NotesDue2034Member 2020-07-31 2020-07-31 0000310158 mrk:Sec1.375NotesDue2036Member 2020-07-31 2020-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) July 31, 2020

 

Merck & Co., Inc.

(Exact name of registrant as specified in its charter)

 

New Jersey

(State or other jurisdiction

of incorporation)

 

1-6571

(Commission

File Number)

 

22-1918501

(I.R.S Employer

Identification No.)

 

2000 Galloping Hill Road, Kenilworth, NJ

(Address of principal executive offices)

   

07033

(Zip Code)

 

 

(Registrant’s telephone number, including area code) (908) 740-4000

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  Trading Symbol(s)  Name of each exchange on which registered
       
Common Stock ($0.50 par value)   MRK  New York Stock Exchange
1.125% Notes due 2021  MRK/21  New York Stock Exchange
0.500% Notes due 2024  MRK 24  New York Stock Exchange
1.875% Notes due 2026  MRK/26  New York Stock Exchange
2.500% Notes due 2034  MRK/34  New York Stock Exchange
1.375% Notes due 2036  MRK 36A  New York Stock Exchange

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.

 

Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on July 31, 2020, regarding earnings for the second quarter of 2020, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.

 

This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)       Exhibits

 

Exhibit 99.1 Press release issued July 31, 2020, regarding earnings for the second quarter of 2020

 

Exhibit 99.2 Certain supplemental information not included in the press release

 

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 

 

  

 SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

    Merck & Co., Inc.
     
Date: July 31, 2020 By: /s/ Faye C. Brown
    FAYE C. BROWN
    Senior Assistant Secretary